Testosterone Replacement products were silent players of the pharma industry dating back since 1950. Manufacturers such as Allergan, Endo Pharmaceuticals had their heels dug in, but it was a slump until AndroGel a brand by AbbVie entered the market with a boom in 2011. A year earlier in 2010, Eli Lilly had launched Axiron, but it was AbbVie who introduced the term "Low-T" to the world.
Low testosterone actually means a decrease in testosterone hormone levels in males, which is common after the age of 50. AbbVie specifically targeted this age group to create a superfluous market. People were now concerned about low testosterone levels, and Androgel was portrayed as a miracle product, until the day a realization dawned that Testosterone therapies are actually triggering cardiovascular risks, stroke and even death in men.
The trial buzz is on and affected claimants are still contacting law firms to associate with the MDL. Intaking cases is of utmost importance to a law firm, at the same time validating them by way of a thorough review of records to ascertain Proof of Usage (POU) and Proof of Injury (POI) is of equal significance. Evidence to be looked for in potential Low-T cases:
- Indication of Testosterone usage in Medical Records
- Evaluation of Risk and Confounding factors from Past Medical History
- Pharmacy records indicating usage of Testosterone
- Sticker labels of Testosterone gels.
- Duration/Formulation of Testosterone usage
- Follow-up complications and their treatment after initiation of Testosterone therapy in medical records.